Amgen Inc. said on Monday that it has won an appeals court ruling that prevents an Israeli company from seeking royalties on its Enbrel arthritis treatment.

Israel Bio-Engineering Project sued Amgen and its marketing partner Wyeth, claiming that Enbrel infringed on a U.S. patent held by the project.

The Los Angeles U.S. District Court upheld a finding that Yeda Research and Development Co., which licenses inventions of the Weizmann Institute of Science in Israel, is at least a part owner of the patent in question.

Yeda “has made it quite clear that it wants no part of the litigation (and) without a complete ownership interest … IBEP lacks standing to sue for infringement,” the appeals court said.

Shares in Amgen were down 1.7 percent ($1.18) to $70.32 in midday trading Monday. The stock was still suffering from a report last week that Amgen’s extended-use anemia treatment, Aranesp, may increase the change of death in heart patients.